AAM
ENTA icon

Advisors Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Advisors Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,439
Closed -$229K – 1495
2020
Q4 		$229K Sell
5,439
-85
-2% -$3.74K ﹤0.01% 1189
2020
Q3 		$253K Sell
5,524
-103
-2% -$4.99K ﹤0.01% 1111
2020
Q2 		$283K Sell
5,627
-61
-1% -$3.16K 0.01% 1080
2020
Q1 		$293K Sell
5,688
-274
-5% -$14.6K 0.01% 1009
2019
Q4 		$368K Sell
5,962
-79
-1% -$4.9K 0.01% 1070
2019
Q3 		$363K Sell
6,041
-130
-2% -$9.66K 0.01% 1056
2019
Q2 		$521K Buy
6,171
+2,181
+55% +$196K 0.01% 998
2019
Q1 		$381K Buy
+3,990
New +$358K 0.01% 1153

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Advisors Asset Management's ENTA Position: Q1 2021 in Review

Advisors Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2021, closing a stake of 5,439 shares — an estimated $229K sold.

Advisors Asset Management first reported a position in ENTA in Q1 2019 and held it in 8 quarters. The position peaked at $521K in Q2 2019. 148 funds tracked by Wall St. Rank hold ENTA as of Q1 2021.

  • Advisors Asset Management reported no remaining Enanta Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Advisors Asset Management sold 5,439 Enanta Pharmaceuticals shares in Q1 2021, an estimated $229K.
  • Advisors Asset Management first reported a position in Enanta Pharmaceuticals in Q1 2019 and held it in 8 quarters.
  • Advisors Asset Management's Enanta Pharmaceuticals position peaked at $521K in Q2 2019.
  • 148 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2021.

Based on Advisors Asset Management's 13F filing for Q1 2021, filed 7 May 2021.